Whole-body MRI (WB-MRI) may improve ALS diagnostic certainty. WB-MRI assesses muscle swelling (edema) as a marker for lower ...

Having resilience is so important to me that I’ve written several columns about it. I believe resilience — the ability to cope with and survive change — is a skill ALS patients should hone to navigate ...

Oral PrimeC for ALS significantly reduced toxic TDP-43 protein levels in a Phase 2b trial. PrimeC also slowed functional decline and extended survival by about 15 months. The treatment was well ...

Former Tennessee Titans football player Chris Johnson is sharing his diagnosis with ALS at age 39. The ex-NFL player says he hopes to raise awareness and encourage testing for the rare disease.

TRCN-1023, an experimental treatment for ALS, aims to restore UNC13A function. It is designed to improve communication between nerves and muscles. Global Phase 1/2 clinical trials are underway to ...

AMX0114, an investigational therapy for ALS, showed safety and good tolerability at its lowest dose in a first-in-human clinical trial. Developer Amylyx is now advancing that trial, called LUMINA, to ...

A clinical trial in Europe is testing the safety and pharmacological properties of LTX-002 as a potential treatment for ALS. The new therapy targets dysregulated fat metabolism, a key contributor to ...

Nura Bio raised $73.8 million to advance two experimental SARM1 inhibitors. The therapies are designed to block SARM1, a ...

Lower adiponectin and IL-10 levels are linked to faster ALS progression and shorter survival. These molecules may serve as biomarkers for ALS prognosis and guide new treatment development. Initial ...